Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mass spectrometry-based clinical proteomics.

Wolfgang Pusch1, Mark T Flocco, Sau-Mei Leung

  • 1Bruker Daltonik GmbH, Fahrenheitstrasse 4, D-28359 Bremen, Germany. WPU@bdal.de

Pharmacogenomics
|July 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discriminative Index: A Novel Indicator for Evaluating Machine Learning Algorithms in Laboratory Medicine.

Diagnostics (Basel, Switzerland)·2026
Same author

Interpreting MALDI imaging data for rare types of ampullary cancer using machine learning.

NPJ systems biology and applications·2026
Same author

Fourier-transform infrared spectroscopy reliably differentiates Klebsiella pneumoniae outbreak isolates.

Journal of microbiological methods·2025
Same author

Detection of colistin resistance from Escherichia colicolonies grown on agar cultures and bacterial pellets obtained from positively flagged blood cultures by MALDI-TOF MS-based rapid assay: aproof-of-concept study.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2025
Same author

Integrating MALDI-MSI-Based Spatial Proteomics and Machine Learning to Predict Chemoradiotherapy Outcomes in Head and Neck Cancer.

International journal of molecular sciences·2025
Same author

Performance of direct detection of <i>Mycobacterium tuberculosis</i> within <i>Mycobacterium tuberculosis</i> complex by routine MALDI-TOF for diagnosis using species-specific lipid fingerprint.

Microbiology spectrum·2025
Same journal

Adherence to international pharmacogenomic recommendations in pediatric cancer care: a cohort analysis embedded within the MARVEL-PIC randomized trial.

Pharmacogenomics·2026
Same journal

Closely similar tacrolimus morning troughs and graft function across the recipients' common <i>ABCB1</i> polymorphisms (<i>c.2677G>T/A</i>, <i>c.1236C>T</i>, <i>c.3435C>T</i>) early after renal transplantation.

Pharmacogenomics·2026
Same journal

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.

Pharmacogenomics·2026
Same journal

Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: "It's no different from your blood type".

Pharmacogenomics·2026
Same journal

Optimizing pharmacogenomics workflows: a qualitative evaluation of clinical service delivery models.

Pharmacogenomics·2026
Same journal

Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases.

Pharmacogenomics·2026
See all related articles

Mass spectrometry (MS) is a gold standard for protein analysis and is expanding into clinical diagnostics. Advanced MS techniques and bioinformatics aid in discovering disease biomarkers in body fluids for early diagnosis.

Area of Science:

  • Biochemistry
  • Proteomics
  • Clinical Diagnostics

Background:

  • Mass spectrometry (MS) is a gold standard for protein identification and analysis in proteomics.
  • MS is increasingly used in life sciences, including nucleic acid analysis for SNP genotyping.
  • Advancements in MS instrumentation, sample prep, and bioinformatics expand its applications beyond traditional protein analysis.

Purpose of the Study:

  • To review the latest developments in using MS for biomarker discovery in clinical proteomics.
  • To highlight the role of MS in identifying individual biomarkers and complex biomarker patterns.
  • To emphasize the growing importance of predictive markers for early disease diagnosis.

Main Methods:

  • Generating protein profiles (mass to charge ratio vs. signal intensity) from body fluids (serum, saliva, urine).

Related Experiment Videos

  • Utilizing sophisticated bioinformatics algorithms to analyze complex mass spectra.
  • Applying MS for both individual biomarker identification and discovery of multi-analyte patterns.

    • Main Results:

    • MS enables the detection of changes in protein levels indicative of disease states.
    • Complex biomarker patterns, often not apparent to the human eye, can be identified using advanced algorithms.
    • MS is a powerful tool for screening and discovery in novel application areas like clinical diagnostics.

    Conclusions:

    • MS is crucial for generating protein profiles from biofluids for clinical proteomics.
    • Bioinformatics is essential for uncovering hidden biomarker patterns in mass spectra.
    • MS facilitates the discovery and identification of biomarkers for predictive medicine and early disease diagnosis.